Enanta Posts Q3 Loss While Advancing RSV and Immunology Pipelines and Securing a $75M ATM
ENTA has more than doubled off its 52-week low of $6.45.
Summary
Enanta Pharmaceuticals posted a Q3 net loss of $19.5M, advanced its RSV and immunology pipelines, and disclosed a new $75M at-the-market equity facility.
Key Events · Earnings and Guidance · ENTA
-
Q3 FY2026 Financial Results
A net loss of $19.5M ($0.67/share) was recorded on $14.4M in royalty revenue, with cash and marketable securities totaling $211.5M as of June 30, 2026.
-
RSV Program Advancement
A registrational Phase 2b/3 trial (RESOLVE) is planned to start in Q4 2026, while the pediatric Phase 2b study (LOTUS) began in Q3 2026, with data expected in 2027.
-
Immunology Pipeline Progress
Dosing has begun in the Phase 1 trial of EDP-978 (KIT inhibitor), with topline data anticipated in Q4 2026. An IND filing for STAT6 is expected in H2 2026, and candidate selection for MRGPRX2 is also slated for H2 2026.
-
$75M ATM Facility Established
On July 2, 2026, Enanta entered into an Open Market Sale Agreement for up to $75M in at-the-market stock sales; no shares have been issued yet.
Analysis · ENTA · Life Sciences
Enanta's Q3 results reflect a net loss of $19.5M on $14.4M in royalty revenue, yet its $211.5M cash position extends the runway into fiscal 2029. The RSV drug zelicapavir is moving toward registrational trials, and several immunology programs are entering the clinic. A new $75M ATM facility introduces potential dilution, though no shares have been sold. The patent litigation loss against Pfizer is a setback, but a rehearing petition remains pending.
At the time of this filing, ENTA was trading at $13.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.1M. The 52-week trading range was $6.45 to $17.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.